People

Ralph R. Weichselbaum, MD

  • Chair of Radiation and Cellular Oncology
    Daniel K. Ludwig Distinguished Service Professor of Radiation and Cellular Oncology
    Committee on Cancer Biology
    Committee on Clinical Pharmacology and Pharmacogenomics
  • Websites: Research Network Profile
  • Contact: rrw@radonc.uchicago.edu
  • Graduate Program: Cancer Biology

University of Illinois
Chicago IL
MD - Medicine
1971

University of Wisconsin
Madison WI
BS - Liberal Arts
1967

Small animal IMRT using 3D printed compensators.
Redler G, Pearson E, Liu X, Gertsenshteyn I, Epel B, Pelizzari C, Aydogan B, Weichselbaum R, Halpern HJ, Wiersma RD. Small animal IMRT using 3D printed compensators. Int J Radiat Oncol Biol Phys. 2020 Dec 26.
PMID: 33373659

Cooperation of genes in HPV16 E6/E7-dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens.
Böttinger P, Schreiber K, Hyjek E, Krausz T, Spiotto MT, Steiner M, Idel C, Booras H, Beck-Engeser G, Riederer J, Willimsky G, Wolf SP, Karrison T, Jensen E, Weichselbaum RR, Nakamura Y, Yew PY, Lambert PF, Kurita T, Kiyotani K, Leisegang M, Schreiber H. Cooperation of genes in HPV16 E6/E7-dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens. Carcinogenesis. 2020 Nov 13; 41(11):1605-1615.
PMID: 32221533

Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?
Prasanna PG, Woloschak GE, DiCarlo AL, Buchsbaum JC, Schaue D, Chakravarti A, Cucinotta FA, Formenti SC, Guha C, Hu DJ, Khan MK, Kirsch DG, Krishnan S, Leitner WW, Marples B, McBride W, Mehta MP, Rafii S, Sharon E, Sullivan JM, Weichselbaum RR, Ahmed MM, Vikram B, Coleman CN, Held KD. Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks? Radiat Res. 2020 11 10; 194(5):452-464.
PMID: 33045077

Oligometastasis: Past, Present, Future.
Gutiontov SI, Pitroda SP, Weichselbaum RR. Oligometastasis: Past, Present, Future. Int J Radiat Oncol Biol Phys. 2020 Nov 01; 108(3):530-538.
PMID: 32976785

The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
Ding XC, Wang LL, Zhu YF, Li YD, Nie SL, Yang J, Liang H, Weichselbaum RR, Yu JM, Hu M. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes. Front Immunol. 2020; 11:580335.
PMID: 33224142

RIG-I-Like Receptor LGP2 Is Required for Tumor Control by Radiotherapy.
Zheng W, Ranoa DRE, Huang X, Hou Y, Yang K, Poli EC, Beckett MA, Fu YX, Weichselbaum RR. RIG-I-Like Receptor LGP2 Is Required for Tumor Control by Radiotherapy. Cancer Res. 2020 Dec 15; 80(24):5633-5641.
PMID: 33087322

Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial.
Luke JJ, Onderdonk BE, Bhave SR, Karrison T, Lemons JM, Chang P, Zha Y, Carll T, Krausz T, Huang L, Martinez C, Janisch LA, Hseu RD, Moroney JW, Patel JD, Khodarev NN, Salama JK, Ott PA, Fleming GF, Gajewski TF, Weichselbaum RR, Pitroda SP, Chmura SJ. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 Dec 15; 26(24):6437-6444.
PMID: 33028595

p50 mono-ubiquitination and interaction with BARD1 regulates cell cycle progression and maintains genome stability.
Wu L, Crawley CD, Garofalo A, Nichols JW, Campbell PA, Khramtsova GF, Olopade OI, Weichselbaum RR, Yamini B. p50 mono-ubiquitination and interaction with BARD1 regulates cell cycle progression and maintains genome stability. Nat Commun. 2020 10 06; 11(1):5007.
PMID: 33024116

Nanoscale metal-organic frameworks for x-ray activated in situ cancer vaccination.
Ni K, Lan G, Guo N, Culbert A, Luo T, Wu T, Weichselbaum RR, Lin W. Nanoscale metal-organic frameworks for x-ray activated in situ cancer vaccination. Sci Adv. 2020 Oct; 6(40).
PMID: 33008911

Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells.
Candas-Green D, Xie B, Huang J, Fan M, Wang A, Menaa C, Zhang Y, Zhang L, Jing D, Azghadi S, Zhou W, Liu L, Jiang N, Li T, Gao T, Sweeney C, Shen R, Lin TY, Pan CX, Ozpiskin OM, Woloschak G, Grdina DJ, Vaughan AT, Wang JM, Xia S, Monjazeb AM, Murphy WJ, Sun LQ, Chen HW, Lam KS, Weichselbaum RR, Li JJ. Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. Nat Commun. 2020 09 14; 11(1):4591.
PMID: 32929084

View All Publications